AI Article Synopsis
- The first major trial for multiple sclerosis (MS) therapy, comparing corticotrophin to placebo, showed that large studies could be done for this variable disease.
- Adrenocorticotrophic hormone was eventually replaced by intravenous methylprednisolone (IVMP) for treating acute flare-ups due to its effectiveness in controlling inflammation.
- While long-term corticosteroid use has risks, pulsed IVMP appears to reduce brain atrophy, suggesting that more research on this technique could be beneficial.
Article Abstract
Forty-five years ago the first large multicentre, randomized, double-blinded, controlled trial of a potential therapy for multiple sclerosis (MS) was completed testing corticotrophin versus placebo. It demonstrated the feasibility of such a trial in an illness which is as variable, from patient to patient, as MS. Adrenocorticotrophic hormone was soon replaced by intravenous methylprednisolone (IVMP) as therapy for acute exacerbations, to control acute inflammatory responses. Long-term therapy with corticosteroids is fraught with complications. Pulsed IVMP has been widely used as an alternative, but few formal studies have been done. One, however, suggested that treated patients had less brain atrophy, and further study of this technique may be indicated.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Infection and pulmonary vascular diseases consortium: United against a global health challenge.
Pulm Circ
October 2024
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine University of Kansas Medical Center Kansas City Kansas USA.
Leveraging the potential of virtual platforms in the post-COVID-19 era, the Infection and Pulmonary Vascular Diseases Consortium (iPVDc), with the support of the Pulmonary Vascular Research Institute (PVRI), launched a globally accessible educational program to highlight top-notch research on inflammation and infectious diseases affecting the lung vasculature. This innovative virtual series has already successfully brought together distinguished investigators across five continents - Asia, Europe, South and North America, and Africa. Moreover, these open global forums have contributed to a comprehensive understanding of the complex interplay among immunology, inflammation, infection, and cardiopulmonary health, especially concerning pulmonary hypertension and related pulmonary disorders.
View Article and Find Full Text PDFHabitat structure and an introduced predator limit the abundance of an endangered ground-nesting bird.
Ecol Appl
December 2024
Evolution & Ecology Research Centre, University of New South Wales, Sydney, New South Wales, Australia.
Understanding the factors that limit the abundance of threatened species is critical for the development of effective conservation strategies. However, gaining such knowledge from monitoring programs and using it to inform decision-making for rare species can be difficult due to methodological issues posed by the problems of distinguishing true absences from false absences and the analysis of datasets dominated by zero counts. The plains-wanderer (Pedionomus torquatus) is a critically endangered ground-nesting bird that occurs in grasslands of southeastern Australia.
View Article and Find Full Text PDFDesign and development of a series of 4-(piperazin-1-yl)pyrimidines as irreversible menin inhibitors.
Eur J Med Chem
December 2024
Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China; University of Chinese Academy of Sciences, NO.19A Yuquan Road, Beijing, 100049, China. Electronic address:
Article Synopsis
- * Researchers created a new series of irreversible menin inhibitors, with compound 37 being the standout candidate, showing selectivity and potency against leukemic cells expressing MLL fusion proteins.
- * Compound 37 works through a unique mechanism by reducing menin protein levels and downregulating its gene transcription, potentially overcoming resistance to current menin inhibitors and demonstrating promising effects in further studies.
How I Treat patients with AML using azacitidine and venetoclax.
Blood
September 2024
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States.
Article Synopsis
- Despite its benefits, the azacitidine-venetoclax combination (AZA-VEN) can also cause severe myelosuppression and a heightened risk of infections compared to azacitidine alone.
- Effective management strategies include prevention of tumor lysis syndrome, minimizing infection risks, ensuring adequate recovery time between treatment cycles, and adjusting treatment duration based on blood count recovery to optimize patient care.
German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson's disease: new spotlights on diagnostic procedures and non-pharmacological interventions.
J Neurol
November 2024
Hertie Institute for Clinical Brain Research, Department of Neurodegenerative Diseases, Eberhard Karls Universität Tübingen, Tübingen, Germany.
Background And Objective: Cognitive impairment and dementia as well as affective disorders are common and debilitating syndromes that develop in people with Parkinson's disease (PwPD). The authors summarized recommendations for the 2023 updated German guidelines on "Parkinson's disease" from the German Neurological Society (DGN), focusing on the diagnosis and treatment of these disorders.
Methods: The recommendations were based on literature reviews, other relevant guidelines, and expert opinions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!